Fig. 1From: Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcomaStudy Schema. This is a randomized, non-comparative Phase II study designed to detect pathologic and immunologic biomarkers of response to checkpoint blockade in resectable, treatment naive primary or locally recurrent (a) dedifferentiated liposarcoma (DDLPS) of the retroperitoneum and (b) undifferentiated pleomorphic sarcoma (UPS) of the trunk or extremitiesBack to article page